HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coty/Rimmel Targeted With Suit Over Lash Accelerator Claims

This article was originally published in The Rose Sheet

Executive Summary

Lawsuit seeking class-action status against Coty alleges that lengthening and multiplying claims for the firm’s Rimmel London Lash Accelerator are “false, misleading and are reasonably likely to deceive the public.”

You may also be interested in...

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.

Aggressive Claims, FDA Warnings Make Beauty A Bull’s Eye For Litigation

Class-action suits against beauty firms on the rise as industry pushes the envelope with claims and FDA warning letters draw attention from class-action law firms, legal experts note. Hogan Lovells attorney Mark Goodman says: “I don’t see this [trend] going away anytime soon.”

Clinique’s Scientific Language Misleads Consumers – Suit

Consumer lawsuit seeking class-action certification faults the Estee Lauder Companies for scientific language in its Clinique marketing that implies FDA approval, and for performance claims that can’t be true or they’d render the product a drug. Plaintiff’s lawyer says anti-aging marketers are “pushing the envelope.”

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts